Article Text

Download PDFPDF
Long term donepezil did not delay institutionalisation or progression to disability in patients with Alzheimer’s disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 Q In patients with Alzheimer’s disease (AD), does donepezil delay entry to institutional care or progression of disability?

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★☆☆ Neurology ★★★★★★☆ Geriatrics ★★★★★★☆


Embedded ImageDesign:

randomised controlled trial (AD2000 study).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {patients, healthcare providers, data collectors, and outcome assessors}.*

Embedded ImageFollow up period:

3 years.

Embedded ImageSetting:

22 hospitals in the UK.

Embedded ImagePatients:

566 patients (59% women, median age 75–76 y) who were referred to memory clinics with a suspected DSM-IV diagnosis of dementia of Alzheimer type, with or without coexisting vascular dementia; had a regular carer; lived in the community; were not taking a cholinesterase inhibitor; and had no contraindications to donepezil.

Embedded ImageIntervention:

during a 12 week run in period, patients were allocated to donepezil, 5 mg/day (n = 283), or …

View Full Text


  • * See glossary.

  • Information provided by author.

  • For correspondence: AD2000 Collaborative Group, University of Birmingham Clinical Trials Unit, Birmingham, UK. AD2000{at}

  • Source of funding: NHS Executive R&D (West Midlands).